Please visit answersincme.com/TSM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the rationale, latest evidence, and practical considerations for adding a locoregional approach (eg, tumor-treating fields therapy, stereotactic body radiation therapy) to systemic immunotherapy for patients with advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Outline the mechanisms of action of novel locoregional therapies and their combination with immunotherapies to treat advanced NSCLC; Describe the evidence on combining novel locoregional therapies with systemic; Immunotherapy for advanced NSCLC; and Identify practical patient-centered strategies for the evidence-based use of combined locoregional and systemic immunotherapy treatment in advanced NSCLC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related